GlaxoSmithKline Receives FDA 'Complete Response' Letter for Cervical Canc... (rget _new http://www.who.int/vaccine

HOME >> MEDICINE >> NEWS

GlaxoSmithKline Receives FDA 'Complete Response' Letter for Cervical Cancer Vaccine

Date:12/17/2007

rget="_new">http://www.who.int/vaccine_research/diseases/hpv/en/ Accessed on May

2, 2007.

2. Jemal A, Murray T, Ward E, Sammuels A et al. Cancer Statistics, 2005.

Cancer Journal for Clinicians 2005; 55; 10-30

Enquiries:

UK Media enquiries: Philip Thomson (020) 8047 5502

Alice Hunt (020) 8047 5502

Joss Mathieson (020) 8047 5502

Claire Brough (020) 8047 5502

US Media enquiries: Nancy Pekarek (215) 751 7709

Mary Anne Rhyne (919) 483 2839

Liad Diamond (919) 483 2839

European Analyst/Investor enquiries: David Mawdsley (020) 8047 5564

Sally Ferguson (020) 8047 5543

US Analyst/ Investor enquiries: Frank Murdolo (215) 751 7002

Tom Curry (215) 751 5419

Biologicals: Stella Gu +32 2 656 3533

Alice Grasset +32 2 656 8774

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine news :

1. GlaxoSmithKline Responds to JAMA Articles
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results
4. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
5. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
6. GlaxoSmithKline Aids California Fire Relief Efforts
7. Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
8. GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
9. Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds
10. GlaxoSmithKline Presents Innovative Neuroscience Pipeline
11. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store

Post Your Comments:

(Date:12/1/2009)...wswire/ -- Reportlinker.com announces that a new m...e: ,, Global In Vitro Diagnostics Market Analy...tlinker.com/p0166596/Global-In-Vitro-Diagnostics-M...lobal In Vitro Diagnostics Market Analysis and For..."Global In Vitro Diagnostics (IVD) Market Analysis...

(Date:12/1/2009)...e-USNewswire/ -- The Kerlan Jobe Orthopaedic Clini...reed to pay the United States $3 million to settle...om HealthSouth Corporation, the Justice Department...es allegations that HealthSouth paid kickbacks to ...nations to the Kerlan Jobe Foundation, loan forgiv...

(Date:12/1/2009)...but more easily identified, study finds , ...c resonance imaging test is highly effective at de...called placenta accreta, researchers report. , ... a fetus attaches too deeply to a woman,s uterus. ...f the uterine wall, rupturing blood vessels and pu...

(Date:12/1/2009)...ire-FirstCall/ -- With employee benefit choices be... are providing self-service decision-making tools ...g to a new survey by Watson Wyatt, a leading globa...er these tools believe they lead employees to make...to the survey, 45 percent of companies offered emp...

(Date:12/1/2009)...RNewswire/ -- Edifecs, Inc., the proven leader in ...lutions announced an enhanced release of Edifecs X... HIPAA 5010 migrations. XEngine Translator provide...ws generation of test data and permits two-way tra...us addressing most requirements for organizations ...

[0] Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 [0] Los Angeles' Kerlan Jobe Orthopaedic Clinic Pays $3 Million to Settle Kickback Allegations [0] Serious Pregnancy Complication Detected With MRI [0] Employers Plan to Increase Use of Self-Service Decision-Making Technology For Open Enrollment, Watson Wyatt Survey Finds [0] Edifecs Delivers Enhanced HIPAA 4010A1 to 5010 Migration Capabilities for Healthcare Organizations

... EPS Growth of 53.3 Percent) - , , - Confirms Dou...reased 2009 Dividend by 11 Percent - , , ABBOTT... announced financial results for the first quarter... above the mid-point of Abbott,s previous first-qu...

...upply today announced that after only 20 months it...will now officially be known as Simplex Healthcare... April 15, 2009 -- Simplex Diabetic Supply today a...ur company has accomplished our initial mission of...

...BRA and Medicare considerations; people with disab...althcare coverage , Belle...rovisions in the 2009 American Recovery and Reinve...ing to Allsup , a leading provider of Social Secu...

...to represent executive board and individual union ...on on recognition of collective bargaining rights ...April 15, 2009 -- Taubman Kimelman & Soroka ,...by Local 2222 of the American Federation of Govern...

... issue of the Journal of Clinical Sleep Medicine ...ing sleep disorders in adults with a traumatic bra...ay result in the objective resolution of the sleep...sleep apnea (OSA), three months of treatment with ...

...arasites in east and west Africa carry different r...tiveness of sulfadoxine as an antimalarial drug ma...ations for the manner in which malaria control cam...ffective than working in isolation in each country...

Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009 Simplex Diabetic Supply Changes Its Name to Simplex Healthcare Jobless Should Evaluate COBRA, Medicare in Light of 2009 Recovery Act Taubman Kimelman & Soroka Retained by AFGE Local 2222 to Advise in Organizing of New York and New Jersey Transportation Security Officers Treating sleep disorders in people with traumatic brain injury may not eliminate symptoms Discovery of variations in resistance to sulfadoxine across Africa

(Date:12/1/2009)... Merck & Co., Inc. today announ...A) has approved ZEGERID OTC(TM) (omeprazole 20 mg/...-counter treatment of frequent heartburn. ZEGERID...-Plough HealthCare Products, Inc., the consumer he...g-Plough and Merck merged on November 3, 2009. ,...

(Date:12/1/2009)...e/ -- Reportlinker.com announces that a new market..., Latin American Pharmaceutical Market Outlook...ecasts and growth opportunities ,, http://w...ceutical-Market-Outlook-To-2014-Policy-environment...s.html ,, The $28.8bn Latin American market ...

(Date:12/1/2009)... -- Reportlinker.com announces that a new market r..., The Future of Oncology Therapeutics - Market Fo... Pipeline and Deals Analysis ,, http://www.re...rapeutics---Market-Forecasts-to-2015-Competitive-B...ml ,, Summary ,, The author has released ...

Breaking Medicine Technology:FDA Approves ZEGERID OTC(TM) for Over-the-Counter Treatment of Frequent Heartburn 2 FDA Approves ZEGERID OTC(TM) for Over-the-Counter Treatment of Frequent Heartburn 3 FDA Approves ZEGERID OTC(TM) for Over-the-Counter Treatment of Frequent Heartburn 4 Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities 2 Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities 3 Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities 4 Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities 5 Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities 6 Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities 7 Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities 8 Reportlinker Adds The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2 Reportlinker Adds The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3 Little Company of Mary Proceeds with Plans to Transform Hospital Campus 59199 1 Little Company of Mary Proceeds with Plans to Transform Hospital Campus 59199 2 Strategic Alliance Between Televisa and Genomma Lab 59195 1 Anpath Group Inc Announces Expansion of Its Distributor Network 5362 1 Anpath Group Inc Announces Expansion of Its Distributor Network 5362 2 Anpath Group Inc Announces Expansion of Its Distributor Network 5362 3

[0] FDA Approves ZEGERID OTC(TM) for Over-the-Counter Treatment of Frequent Heartburn [0] Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities [0] Reportlinker Adds The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

...Pharmacyclics, Inc.,(Nasdaq: PCYC ) today announ...,1 dose-escalation study to evaluate the safety an...elective inhibitor of Bruton,s tyrosine kinase, or...lapsed or refractory B-cell,non-Hodgkin,s lymphoma...r to,be tested in humans, and is Pharmacyclics, fo...

... Pharmaceuticals Corp. ("Raptor" or the "Company")...pointment of Patrice P. Rioux, M.D., Ph.D., as Chi...onsible for the clinical and regulatory advancemen...rams. , , (Logo: http://www.newscom.com/cgi-bi...ical programs include Delayed-Release Cysteamine (...

Other Medicine Technology:Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 2 Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 3 Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 4 Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 5 Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer 2 Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer 3 Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer 4 Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer 5

Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer

Innova 3100 Water Bath Shaker

55D Double Platform Shaker 11 x 14

Innova 5000 Muti-Tier Shaker

...up to 16 of AutoGen's tube units to prepare 96 sam...te for bacterial cultures and enzyme reactions, su... simplify your DNA extraction process by preparing...lacing our 6-hole tube units directly onto one of ...

Medicine Products:

Innova 3100 Water Bath Shaker 55D Double Platform Shaker 11 x 14 Innova 5000 Muti-Tier Shaker AutoIncubator 96

GlaxoSmithKline Receives FDA 'Complete Response' Letter for Cervical Canc...(rget _new http://www.who.int/vaccine_res...),Health